(Alliance News) - PureTech Health PLC on Friday noted the pricing of its founded entity Seaport Therapeutics Inc for its planned initial public offering on the Nasdaq.
The Boston, Massachusetts-based biotech and pharmaceutical company said Seaport's upsized IPO is of around 14.2 million shares at a price to the public of USD18.00 per share, at the top end of the target range.
The gross proceeds to Seaport from the offering are expected to be USD254.9 million.
The shares are expected to start trading on the Nasdaq Global Select Market on Friday, with the offering anticipated to close on Monday.
PureTech shares rose 8.9% to 138.91 pence each on Friday morning in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Corporate News Finance and Instruments Pharmaceuticals Health Care

SINGAPORE, May 26 (Reuters) - Canada's Manulife Financial Corp has raised S$500 million ($392 million) through a 10-year subordinated Tier-2 bond w...


Gresham House Energy Storage Fund PLC - London-based investor in utility-scale battery energy storage systems, managed by Gresham House Asset Manageme...


Aterian PLC - minerals exploration and trading in Africa, including copper-silver projects in Morocco and Botswana and an exploration licence in Rwand...